Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of screening
• People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer), confirmed through a tissue or cell sample, and who have been treated with a combined chemotherapy and radiation therapy (given at the same time) for stage III lung cancer that cannot be surgically removed
• People who can provide a tumour tissue sample that was collected before their chemotherapy and radiation treatment
• People whose tumour tests positive for a protein called PD-L1 at a level of 1% or higher, confirmed by a central laboratory
• People whose tumour tests negative for certain gene changes known as EGFR and ALK mutations
• People whose cancer has not grown or spread after completing their chemotherapy and radiation treatment
• People who received at least 2 rounds (cycles) of platinum-based chemotherapy at the same time as their radiation therapy
• People who received a total radiation dose of between 54 and 66 Gray (a unit used to measure radiation) as part of their treatment
• People who are in good general health, rated as 0 or 1 on a standard medical fitness scale (meaning fully active or able to carry out light activity)
• People whose organs (such as kidneys, liver, and bone marrow) are functioning well enough as shown by blood tests

Who may not be able to join:

• People who have had another type of cancer in the past, unless it was fully treated with no signs of return and has not required active treatment in the last 3 years, or it was a certain low-risk skin cancer or an early-stage non-invasive cancer with no current signs of disease
• People whose lung cancer is a mixed type involving both small cell and non-small cell lung cancer
• People who received their chemotherapy and radiation therapy separately (one after the other) rather than at the same time
• People whose lung cancer got worse or spread during their combined chemotherapy and radiation treatment
• People who still have significant side effects (above a moderate level) from their previous chemotherapy and radiation treatment, other than hair loss
• People who developed moderate or severe lung inflammation (pneumonitis) as a result of their previous treatment
• People who have a history of certain lung scarring or inflammation conditions, or who currently have active lung inflammation, active lung infection, active fluid around the lungs, or ongoing lung scarring — regardless of cause
• People who have or have had active autoimmune or inflammatory conditions (diseases where the immune system attacks the body), with some exceptions (confirm with trial site)
• People who have an active infection with a virus called Epstein-Barr virus (EBV), or are suspected of having a long-term active EBV infection
• People who have used medications that suppress the immune system within 14 days before starting the study drug

Important: Always verify eligibility with the trial site directly before applying.